natgillin/translations-raw huggingface dataset:
Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX (Study II) were demonstrated in the DLQI (Dermatology Life Quality Index).
Dermatology Life Quality Index, DLQI), u usporedbi s placebom (ispitivanja I i II) i u usporedbi s MTX-om (ispitivanje II).
Significant improvements in the quality of life evaluations measured during the study were also observed with Kentera.
S Kenterom zapaženo je i znatno poboljšanje u procjenama kvalitete života izmjerene tijekom ispitivanja.
Significant improvements were seen in physician’s clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient’s assessment of symptoms.
Značajna poboljšanja uočena su u liječnikovoj ukupnoj procjeni aktivnosti autoinflamatorne bolesti: ukupna procjena aktivnosti autoinflamatorne bolesti, procjena kožne bolesti (urtikarijski kožni osip), artralgija, mijalgija, glavobolja/migrena, konjunktivitis, umor/malaksalost, procjena drugih povezanih simptoma i bolesnikova procjena simptoma.
Significant increases in plasma
Očekuju se povišene
Significant increases in plasma
Očekuju se značajna povišenja
Significant inhibition of inflammatory signs in both sacroiliac joints and the spine was observed in the Cimzia- treated patients (all dose group), in the overall axial spondyloarthritis population as well as in the sub- populations of ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Značajna inhibicija znakova upale u sakroilijačnim zglobovima i u kralježnici zabilježeni su i u bolesnika liječenih Cimzijom (skupini svih doza), u ukupnoj populaciji s aksijalnim spondiloartritisom kao i u subpopulaciji s ankilozantnim spondilitisom i ne-radiografskim aksijalnim spondiloartritisom.
Significant positive effects were also noted for each subscale domain of the IIQ and for six of ten quality of life domains, including the incontinence impact domain, of the King’s Health Questionnaire (KHQ) as shown in the table below.
Značajni pozitivni učinci zapaženi su i za svako područje podljestvice upitnika IIQ i za šest od deset područja kvalitete života, uključujući područje utjecaja inkontinencije, Kraljevskog upitnika o zdravlju (King's Health Questionnaire, KHQ) kao što je prikazano u tablici u nastavku.
Significant prolongation of the QT interval may occur when nilotinib is inappropriately taken with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT, and/or food (see section 4.5).
Značajno produženje QT intervala može se pojaviti ako se nilotinib primjenjuje na neodgovarajući način zajedno sa snažnim CYP3A4 inhibitorima i/ili lijekovima za koje se zna da produžuju QT interval i/ili s hranom (vidjeti dio 4.5).
Significant reduction in DAS28 from baseline (mean improvement) of 3.1–3.4 were observed in tocilizumab-treated patients compared to control patients (1.3-2.1).
Kod bolesnika liječenih tocilizumabom primijećeno je značajno smanjenje vrijednosti DAS28 (prosječno poboljšanje) od 3,1–3,4 u odnosu na početnu vrijednost, za razliku od kontrolnih ispitanika (1,3-2,1).
Significant reductions in amprenavir Cmin
Uočena značajna smanjenja Cmin amprenavira kod bolesnika mogu dovesti do
Significant reductions in death/MI/IDR/ST and ST observed in the cangrelor group at 48 hours were maintained at 30 days (Table 4).
Značajna smanjenja u smrti/MI/IDR/ST i ST opažena u skupini s kangrelorom nakon 48 sati održana su nakon 30 dana (Tablica 4).
Significant reductions in exposure and Cmin observed for both
smanjenje izloženosti i Cmin za oba lijeka, amprenavir i
Significant reductions in iPTH, serum calcium-phosphorus product (Ca x P), calcium, and phosphorus were observed in the cinacalcet treated patients compared with placebo-treated patients receiving standard care, and the results were consistent across the 3 studies.
Značajno smanjenje iPTH-a, umnoška serumskog kalcija i fosfora (Ca x P) te kalcija i fosfora, primijećena je u grupi liječenih sinakalcetom, u usporedbi s placebo grupom koja je liječena standardnim načinom i rezultati su bili konzistentni u sve tri studije.
Significant reductions in iPTH, serum calcium-phosphorus product (Ca x P), calcium, and phosphorus were observed in the cinacalcet treated patients compared with placebo-treated patients receiving standard of care, and the results were consistent across the 3 studies.
Značajno smanjenje iPTH-a, umnoška serumskog kalcija i fosfora (Ca x P) te kalcija i fosfora, primijećena je u grupi liječenih sinakalcetom, u usporedbi s placebo grupom koja je liječena standardnim načinom i rezultati su bili konzistentni u sve tri studije.
Significant respiratory depression.
Značajna respiracijska depresija.
Significant response was first observed at Week 2 and maintained through 24 weeks (Table 10).
To se poboljšanje prvi put uočilo u drugom tjednu i održalo se 24 tjedna (Tablica 10).
Significant response was first observed at Week 2 and maintained through 24 weeks (Table 8).
To se poboljšanje prvi put uočilo u drugom tjednu i održalo se 24 tjedna (Tablica 8).
Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin, therefore, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients.
Ribavirin je imao značajne teratogene i/ili embriocidne učinke u svih životinjskih vrsta koje su mu bile izložene, stoga je potreban krajnji oprez kako bi se izbjegla trudnoća u bolesnica i partnerica muških bolesnika.
Significant weight gain has been reported with INVEGA use.
Značajno povećanje težine prijavljeno je pri uzimanju INVEGE.
Significant  APV expected
Očekuje se značajno  APV
Significantly fewer patients in the abacavir group (9 patients, or 6 %) than in the nevirapine group (26 patients, or 17 %) or the efavirenz group (27 patients, or 17 %) discontinued the medicinal productbecause of adverse events.
Značajno manje bolesnika u skupini na abakaviru (9 bolesnika ili 6%) nego u skupini na nevirapinu (26 bolesnika ili 17%) ili skupini na efavirenzu (27 bolesnika ili 17%) prekinulo je uzimanje lijeka zbog nuspojava
Significantly fewer patients in the abacavir group (9 patients, or 6%) than in the nevirapine group (26 patients, or 17%) or the efavirenz group (27 patients, or 17%) discontinued the medicinal product because of adverse events.
Značajno manje bolesnika u skupini na abakaviru (9 bolesnika ili 6%) nego u skupini na nevirapinu (26 bolesnika ili 17%) ili skupini na efavirenzu (27 bolesnika ili 17%) prekinulo je uzimanje lijeka zbog nuspojava (vidjeti donju tablicu).
Significantly fewer patients in the INTELENCE arm reached a clinical endpoint (AIDS-defining illness and/or death) as compared to the placebo arm (p = 0.0408).
Značajno manje bolesnika u skupini liječenoj INTELENCEom dostiglo je kliničku mjeru ishoda (AIDS – vezana bolest i/ili smrt) u odnosu na skupinu koja je primala placebo (p = 0,0408).
Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%).
Značajno manje bolesnica primilo je transfuzije crvenih krvnih stanica u skupini liječenoj epoetinom alfa plus standardna terapija (5,8 % naspram 11,4 %); međutim, značajno više bolesnica imalo je trombotske vaskularne događaje u skupini liječenoj epoetinom alfa plus standardna terapija (2,8 % naspram 1,4 %).
Significantly higher proportions of patients maintained clinical remission and response in the ustekinumab treated groups compared to the placebo group at week 44 (see Table 9).
Značajno veći udio bolesnika održao je kliničku remisiju i odgovor u skupinama liječenim ustekinumabom u usporedbi s placebo skupinom u 44. tjednu (vidjeti tablicu 9).
significantly increased.
ritonavirom.
Significantly more ciclosporin- treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
Značajno više bolesnika liječenih ciklosporinom (n = 13) moralo je zamijeniti terapiju i prebaciti se na takrolimus, nego što se bolesnika liječenih takrolimusom moralo prebaciti na ciklosporin (n = 2) (p = 0,02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
Significantly more patients achieved HbA1c below 7% with liraglutide compared with placebo (52.8% vs 19.5%).
U usporedbi s placebom, značajno više bolesnika je postiglo HbA1c ispod 7% s liraglutidom (52,8% naspram 19,5 %).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (44,4%) nego oni koji su primali placebo (18,3%) (p<0,001).
Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p<0.001).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (44,4%) u usporedbi s onima koji su primali placebo (18,3%) (p<0,001).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali 25 mg alogliptina (49,2%) nego oni koji su primali placebo (34,0%) (p=0,004).
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su primali alogliptin (49,2%) nego oni koji su primali placebo (34,0%) (p<0,004).
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of  7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001).
U 52. tjednu je ciljne razine HbA1c od ≤7,0% postiglo značajno više bolesnika koji su uzimali 25 mg alogliptina s 30 mg pioglitazona i metforminom (33,2%) nego oni koji su uzimali 45 mg pioglitazona s metforminom (21,3%) (p<0,001).
Significantly more patients treated with Jakavi (20.9%) achieved a primary response (p<0.0001) compared to BAT (0.9%).
Značajno više bolesnika liječenih Jakavijem (20,9%) postiglo je primarni odgovor (p<0,0001) u usporedbi s NDT-om (0,9%).
Significantly more placebo recipients flared during Period B (33/62; 53%) than those maintained on abatacept (12/60; 20%; chi-square p<0.001).
Tijekom Razdoblja B bolest se razbuktala u značajno većem broju bolesnika koji su primali placebo (33/62; 53%) nego onih koji su održavani abataceptom (12/60, 20%; hi-kvadrat p < 0,001).
Signifor 0.3 mg solution for injection
Signifor 0,3 mg otopina za injekciju
Signifor 0.3 mg solution for injection pasireotide
Signifor 0,3 mg otopina za injekciju pasireotid
Signifor 0.3 mg: One ampoule of 1 ml solution contains 0.3 mg pasireotide.
Signifor 0,3 mg: Jedna ampula s 1 ml otopine sadrži 0,3 mg pasireotida.
Signifor 0.6 mg solution for injection
Signifor 0,6 mg otopina za injekciju
Signifor 0.6 mg solution for injection pasireotide
Signifor 0,6 mg otopina za injekciju pasireotid
Signifor 0.6 mg: One ampoule of 1 ml solution contains 0.6 mg pasireotide.
Signifor 0,6 mg: Jedna ampula s 1 ml otopine sadrži 0,6 mg pasireotida.
Signifor 0.9 mg solution for injection
Signifor 0,9 mg otopina za injekciju
Signifor 0.9 mg solution for injection pasireotide
Signifor 0,9 mg otopina za injekciju pasireotid
Signifor 0.9 mg: One ampoule of 1 ml solution contains 0.9 mg pasireotide.
Signifor 0,9 mg: Jedna ampula s 1 ml otopine sadrži 0,9 mg pasireotida.
Signifor 20 mg powder and solvent for suspension for injection
Signifor 20 mg prašak i otapalo za suspenziju za injekciju
Signifor 20 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection pasireotide
Signifor 20 mg prašak i otapalo za suspenziju za injekciju Signifor 40 mg prašak i otapalo za suspenziju za injekciju Signifor 60 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 40 mg and Signifor 60 mg are also available in multipacks containing 3 unit packs.
Signifor 40 mg i Signifor 60 mg također su dostupni u višestrukim pakiranjima koja sadrže po 3 jedinična pakiranja.
Signifor 40 mg powder and solvent for suspension for injection
Signifor 40 mg prašak i otapalo za suspenziju za injekciju
Signifor 60 mg powder and solvent for suspension for injection
Signifor 60 mg prašak i otapalo za suspenziju za injekciju
Signifor contains less than 1 mmol sodium (23 mg) per dose, which means it is essentially “sodium-free”.
Signifor sadrži manje od 1 mmol (23 mg) natrija po dozi, što znači da ima zanemarive količine natrija.
Signifor controls over-production of cortisol.
Signifor kontrolira prekomjerno stvaranje kortizola.
Signifor has no or negligible effects on the ability to drive and use machines.
Signifor ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada na strojevima.
Signifor has no or negligible influence on the ability to drive and use machines.
Signifor ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Signifor intramuscular use 40 mg
Signifor primijenjen intramuskularno
Signifor intramuscular use 60 mg
Signifor primijenjen intramuskularno
Signifor is also used for the treatment of adult patients with acromegaly when surgery has failed or is not an option and who are inadequately controlled with other medicines known as ‘somatostatin analogues’.
Signifor se također koristi za liječenje odraslih bolesnika s akromegalijom kod kojih kirurški zahvat nije uspio ili kod kojih kirurški zahvat nije moguć, te koja se ne može kontrolirati na primjeren način lijekovima poznatima pod nazivom „analozi somatostatina“.
Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Signifor je indiciran za liječenje odraslih bolesnika s akromegalijom kod kojih kirurški zahvat nije moguć ili nije postigao izlječenje te koji nisu odgovarajuće kontrolirani terapijom s drugim analogom somatostatina.
Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
Signifor je indiciran za liječenje odraslih bolesnika s Cushingovom bolešću kod kojih kirurški zahvat nije moguć ili kod kojih kirurški zahvat nije uspio.
Signifor is thus able to block the production of ACTH, helping to control the over-production of cortisol and improve the symptoms of Cushing’s disease.
Signifor tako može blokirati proizvodnju ACTH-a, pomažući time u kontroli pretjerane proizvodnje kortizola, te poboljšati simptome Cushingove bolesti.
Signifor is used to treat adults with Cushing’s disease when surgery has failed or is not an option.
Signifor se koristi za liječenje odraslih bolesnika sa Cushingovom bolešću kod kojih kirurški zahvat nije uspio ili kod kojih kirurški zahvat nije moguć.
Signifor may cause your blood sugar to increase.
Signifor bi mogao uzrokovati povećanje šećera u krvi.
Signifor may lower your heart rate.
Signifor bi Vam mogao sniziti brzinu rada srca.
Signifor must not be used in patients with severe liver problems.
Signifor se ne smije koristiti u bolesnika s ozbiljnim problemima jetre.
Signifor powder is a slightly yellowish to yellowish powder in a vial.
Signifor prašak je blago žućkasti do žućkasti prašak u bočici.
Signifor solution for injection is a clear, colourless solution in an ampoule.
Signifor otopina za injekciju je bistra, bezbojna otopina u ampuli.
Signifor suspension must only be prepared immediately before administration.
Suspenzija Signifora smije se pripremiti tek neposredno prije primjene.
Signifor was also shown to be effective in reducing GH and IGF-1 levels in patients with acromegaly.
Utvrđeno je da je Signifor također djelotvoran u smanjivanju koncentracija HR i IGF-1 u bolesnika s akromegalijom.
Signifor was shown to be effective in reducing cortisol levels in patients with Cushing’s disease.
Signifor se pokazao djelotvornim u smanjivanju razina kortizola u bolesnika s Cushingovom bolešću.
Signifor was studied in 165 adult patients with Cushing’s disease where surgery was not appropriate.
Signifor je ispitivan u 165 odraslih bolesnika s Cushingovom bolesti u slučaju kada kirurški zahvat nije bio primjeren.
Signs and symptoms
Farmakodinamička svojstva
Signs and symptoms may include redness in the eye, pain in the eye, vision problems or blurry vision.
Znakovi i simptomi mogu uključivati crvenilo oka, bol u oku, tegobe s vidom ili zamagljen vid.
Signs and symptoms of a severe allergic reaction could include:
Znakovi i simptomi teške alergijske reakcije mogu obuhvaćati:
Signs and symptoms of a severe allergic reaction include:
Znakovi i simptomi teške alergijske reakcije mogu obuhvaćati:
Signs and symptoms of bleeding events might be haematoma of the skin, tar stools, blood in urine, nose bleed, etc.
Znakovi i simptomi krvarenja mogu biti kožni podljev, crna, katranasta stolica, krv u mokraći, krvarenje iz nosa, itd.
Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy.
Znakovi i simptomi dehidracije, uključujući oštećenje bubrega i akutno zatajenje bubrega, prijavljeni su u kliničkim ispitivanjima s agonistima receptora GLP-1, uključujući liraglutid, sastavnicu lijeka Xultophy.
Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in patients treated with liraglutide.
Znakovi i simptomi dehidracije, uključujući oštećenje bubrega i akutno zatajenje bubrega, prijavljeni su u bolesnika liječenih liraglutidom.
Signs and symptoms of hepatitis may include abnormal liver function tests, eye or skin yellowing (jaundice), pain on the right side of your stomach area, or tiredness.
Znakovi i simptomi hepatitisa mogu uključivati odstupanja u nalazima testova jetrene funkcije, žutu boju očiju ili kože (žutica), bol u desnoj strani trbuha ili umor.
Signs and symptoms of infection and sepsis.
Znakovi i simptomi infekcije i sepse.
Signs and symptoms of kidney disease are described in section 4.
Znakovi i simptomi bolesti bubrega opisani su u dijelu 4.
Signs and symptoms of liver disease (hepatitis) such as yellowing of skin and eyes, dark urine, itching, loss of appetite or abdominal pain (uncommon).
znakove i simptome bolesti jetre (hepatitis), kao što su žutilo kože i očiju, tamna mokraća, svrbež, gubitak teka ili bol u trbuhu (manje često).
signs and symptoms of ocular irritation (e.g. burning, stinging, itching, tearing, redness), choroidal detachment following filtration surgery (see 4.4 Special warnings and special precautions for use), decreased corneal sensitivity, diplopia.
znakovi i simptomi iritacije oka (npr. žarenje, probadanje, svrbež, suzenje, crvenilo), ablacija žilnice nakon filtracijske operacije (vidjeti dio 4.4 Posebna upozorenja i mjere opreza pri uporabi), smanjena osjetljivost rožnice, diplopija.
Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.
Znakovi i simptomi predoziranja (samim duloksetinom ili u kombinaciji s drugim lijekovima) uključivali su somnolenciju, komu, serotoninski sindrom, napadaje, povraćanje i tahikardiju.
signs and symptoms of rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults.
znakova i simptoma reumatoidnog artritisa (bolesti imunosnog sustava koja uzrokuje upalu zglobova) u odraslih osoba.
Signs and symptoms of severe infection and the need to obtain urgent medical care.
Znakovi i simptomi teške infekcije i potreba da se dobije hitna liječnička pomoć.
Signs and symptoms of:
znakova i simptoma:
Signs and symptoms reported in the literature after caffeine overdose in preterm infants include hyperglycaemia, hypokalaemia, fine tremor of the extremities, restlessness, hypertonia, opisthotonus, tonic clonic movements, seizures, tachypnoea, tachycardia, vomiting, gastric irritation, gastro- intestinal haemorrhage, pyrexia, jitteriness, increased blood urea and increased white blood cell count, non-purposeful jaw and lip movements.
Znakovi i simptomi zabilježeni u literaturi nakon predoziranja kofeinom u nedonoščadi uključuju hiperglikemiju, hipokalemiju, fini tremor ruku i nogu, nemir, hipertoniju, opistotonus, toničko- kloničke kretnje, napadaje, tahipneju, tahikardiju, povraćanje, nadraženost želuca, gastrointestinalno krvarenje, pireksiju, nervozu, povišenu ureju u krvi i povećan broj bijelih krvnih stanica, nevoljne pokrete čeljusti i usnica.
Signs and symptoms suggestive of an IRR were reported in more than 50% of patients in clinical trials, and were predominantly seen during the first infusion, usually in the first one to two hours.
Znakovi i simptomi koji upućuju na reakcije povezane s infuzijom prijavljeni su u više od 50% bolesnika u kliničkim ispitivanjima, a uglavnom su primijećeni za vrijeme prve infuzije, obično tijekom prvih sat ili dva.
signs and symptoms suggestive of congestive heart failure (Perjeta should be discontinued if symptomatic heart failure is confirmed)
znakovi i simptomi koji ukazuju na kongestivno zatajenje srca (Perjeta se mora trajno obustaviti ako se potvrdi simptomatsko zatajenje srca)
Signs and symptoms that these glands are not working properly may include fatigue (extreme tiredness), weight change or headache and visual disturbances.
Znakovi i simptomi koji pokazuju da te žlijezde ne rade pravilno mogu uključivati izrazit umor, promjenu tjelesne težine ili glavobolju te smetnje vida.
Signs and symptoms that were associated with higher doses and/or were dose limiting were not life-threatening, and included fever, chills, fatigue, nausea, vomiting, headache and hypo- or hypertension.
Znakovi i simptomi koji su bili povezani s višim dozama i/ili su ograničavali dozu nisu bili po život opasni, a uključivali su vrućicu, zimicu, umor, mučninu, povraćanje, glavobolju i hipotenziju ili hipertenziju.
Signs are:
Znakovi su:
Signs include a fever, feeling tired, (persistent) cough, shortness of breath, weight loss, night sweats, diarrhea, wounds, dental problems, burning when urinating or ‘flu- like’ signs.
Ti znakovi uključuju vrućicu, umor, (uporan) kašalj, nedostatak zraka, gubitak tjelesne težine, noćno znojenje, proljev, rane, probleme sa zubima, žarenje pri mokrenju ili simptome nalik gripi.
Signs include a fever, feeling tired, (persistent) cough, shortness of breath, weight loss, night sweats, diarrhea, wounds, dental problems, burning when urinating or ‘flu-like’ signs.
Ti znakovi uključuju vrućicu, umor, (uporan) kašalj, nedostatak zraka, gubitak tjelesne težine, noćno znojenje, proljev, rane, probleme sa zubima, žarenje pri mokrenju ili simptome nalik gripi.
Signs include a fever, feeling tired, (persistent) cough, shortness of breath, weight loss, night sweats, diarrhoea, wounds, dental problems, burning when urinating or ‘flu-like’ signs.
Ti znakovi uključuju vrućicu, umor, (uporan) kašalj, nedostatak zraka, gubitak tjelesne težine, noćno znojenje, proljev, rane, probleme sa zubima, žarenje pri mokrenju ili simptome nalik gripi.
Signs include rash, difficulty in breathing, swelling or feeling faint.
Znakovi uključuju osip, otežano disanje, oticanje ili nesvjesticu.
Signs include shortness of breath, swelling of the feet or changes in your heartbeat.
Oni obuhvaćaju nedostatak zraka, oticanje stopala ili promjene ritma otkucaja srca.